AJANTPHARM
532331Participation In Investor Conference
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
Ajanta Pharma Ltd is a vertically integrated pharmaceutical company headquartered in Mumbai, India. Established in 1973, the company is engaged in the development, manufacturing, and marketing of quality finished dosages, with a strong focus on branded generics. Ajanta Pharma caters to both regulated and emerging markets, supplying prescription products in therapeutic areas such as cardiology, ophthalmology, dermatology, gastroenterology, and pain management.
Participation In Investor Conference
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pls find enclosed newspaper publication for transfer of equity shares to IEPF.
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee Ravi Agrawal Trust
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee Ravi Agrawal Trust
Participation In Investor Conference
Pls find enclosed Intimation w.r.t participation in Investor Conference
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pls find enclosed herewith Earning Call Transcript
Ajanta Pharma Ltd
About
Ajanta Pharma Ltd is a vertically integrated pharmaceutical company headquartered in Mumbai, India. Established in 1973, the company is engaged in the development, manufacturing, and marketing of quality finished dosages, with a strong focus on branded generics. Ajanta Pharma caters to both regulated and emerging markets, supplying prescription products in therapeutic areas such as cardiology, ophthalmology, dermatology, gastroenterology, and pain management.
The company has a significant presence across Asia, Africa, the Middle East, and select regulated markets including the United States.
With an extensive product portfolio and a robust international footprint, Ajanta Pharma operates multiple state-of-the-art manufacturing and R&D facilities approved by global regulatory agencies such as the US FDA, WHO-GMP, and UK MHRA. The company's operational model emphasizes backward integration and a focused approach toward high-growth specialty segments, enabling it to deliver sustainable business performance and enter new geographies.
Business Model & Strategy
Ajanta Pharma earns revenue primarily from the sale of branded generic pharmaceuticals across emerging and regulated markets. The company adopts a differentiated product strategy, focusing on brand-building in selected therapeutic niches such as cardiology, ophthalmology, anti-malarials, and dermatology. Its growth is underpinned by proprietary formulation development, vertical integration, and targeted marketing initiatives to healthcare professionals.
The business is supported by in-house R&D, which accelerates new product launches across global markets, especially the US, Africa, and Asia.
Ajanta Pharma continues to invest in capacity expansion, regulatory accreditation, and deeper market penetration, aiming to strengthen its specialty portfolio. The company's geographic diversification and consistent pipeline of product launches enhance resilience against market-specific volatility. Additionally, Ajanta leverages its US ANDA pipeline and robust supply chain to grow its presence in regulated markets, while maintaining leadership in branded generics within emerging economies.
Management Overview
10 MembersMr.Mannalal B. Agrawal
Non-Executive - Non Independent Director-Chairperson related to PromoterMr.Madhusudan B. Agrawal
Executive DirectorArvindKAgrawal
Chief Financial OfficerMr.Yogesh Mannalal Agrawal
Executive Director-MDMr.Rajesh Mannalal Agrawal
Executive DirectorMr.David Rasquinha
Non-Executive - Independent DirectorMs.Medha Vinay Joshi
Non-Executive - Independent DirectorMr.Rajesh Shashikant Dalal
Non-Executive - Independent DirectorMs.Simi Manohar Lal Thapar
Non-Executive - Independent DirectorGaurangShah
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Featured among Forbes Asia's '200 Best Under a Billion' (2023)
- Awarded Silver in 'India CSR Leadership Awards' for sustainability initiatives (2024)
- Received India's 'Best Corporate Brand' recognition by Economic Times (2023)
- Acknowledged for environmental practices with the CII GreenCo rating (2024)
- Ranked among India's Top 50 Most Trusted Pharmaceutical Brands (Brand Trust Report 2024)
Market Information
Company Timeline
52+ Years of Excellence | 10 Major Milestones
Ajanta Pharma Ltd founded in Mumbai, India
Commenced export operations to emerging markets
Listed on the Bombay Stock Exchange (IPO)
Established dedicated R&D center in Mumbai
Received US FDA approval for manufacturing facility at Paithan, Maharashtra
Entered US generics market with first ANDA approval
Commercial launch of key dermatology and ophthalmology products
Inaugurated new formulation plant at Guwahati, Assam
Expanded specialty portfolio with new product launches in the US and Africa
Recognized for sustainability and ESG leadership by industry associations
The Next Evolution
Contact Information
Registered Office
Ajanta House, Charkop, Kandivli (W)
Tel: 022-66061000 / 25946970,
Fax: 022-66061200 / 66061300,
Email: info@ajantapharma.com; investorgrievance@ajantapharma.com
Website: ajantapharma.com
Corporate Actions
22| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Interim Dividend ₹32 per share | 05 Aug 2026 Wednesday | 05 Aug 2026 Wednesday | - | - |
Interim Dividend ₹28 per share | 10 Nov 2025 Monday | 10 Nov 2025 Monday | - | - |
Interim Dividend ₹28 per share | 06 Nov 2024 Wednesday | 06 Nov 2024 Wednesday | - | - |
Buy Back of Shares | 30 May 2024 Thursday | 30 May 2024 Thursday | - | - |
Interim Dividend ₹26 per share | 08 Feb 2024 Thursday | 08 Feb 2024 Thursday | - | - |
Interim Dividend ₹10 per share | 04 Aug 2023 Friday | 04 Aug 2023 Friday | - | - |
Special Dividend ₹15 per share | 04 Aug 2023 Friday | 04 Aug 2023 Friday | - | - |
Buy Back of Shares | 24 Mar 2023 Friday | 24 Mar 2023 Friday | - | - |
Interim Dividend ₹7 per share | 11 Nov 2022 Friday | 14 Nov 2022 Monday | - | - |
Bonus issue 1:2 | 22 Jun 2022 Wednesday | 23 Jun 2022 Thursday | - | - |
Buy Back of Shares | 13 Jan 2022 Thursday | 14 Jan 2022 Friday | - | - |
Interim Dividend ₹9.50 per share | 09 Nov 2021 Tuesday | 10 Nov 2021 Wednesday | - | - |
Buy Back of Shares | 12 Nov 2020 Thursday | 13 Nov 2020 Friday | - | - |
Interim Dividend ₹9.50 per share | 12 Nov 2020 Thursday | 13 Nov 2020 Friday | - | - |
Interim Dividend ₹13 per share | 15 Nov 2019 Friday | 18 Nov 2019 Monday | - | - |
Buy Back of Shares | 11 Feb 2019 Monday | 12 Feb 2019 Tuesday | - | - |
Interim Dividend ₹9 per share | 09 Nov 2018 Friday | 12 Nov 2018 Monday | - | - |
Interim Dividend ₹7 per share | 23 Mar 2017 Thursday | 25 Mar 2017 Saturday | - | - |
Interim Dividend ₹6 per share | 07 Nov 2016 Monday | 08 Nov 2016 Tuesday | - | - |
Interim Dividend ₹8 per share | 17 Mar 2016 Thursday | 19 Mar 2016 Saturday | - | - |
Dividend ₹6 per share | 25 Jun 2015 Thursday | - | 27 Jun 2015 Saturday | 04 Jul 2015 Saturday |
Stock Split From Rs.5/- to Rs.2/- | 20 Mar 2015 Friday | 23 Mar 2015 Monday | - | - |
₹43,727 Cr.
₹3,505
₹3,796 / 2,330
38.53
₹362.35
9.66
₹90.84
₹2.00
1.71 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 2,076 | 2,680 | 2,916 | 3,457 | 3,841 | 4,293 | 4,743 | 5,625 | 5,993 |
| Expenses | - | - | - | 1,562 | 2,012 | 2,015 | 2,547 | 3,096 | 3,179 | 3,553 | 4,247 | 4,499 |
| Profit | - | - | - | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 | 1,135 |
| Tax | - | - | - | 127 | 196 | 246 | 197 | 157 | 298 | 269 | 322 | 358 |
| EPS | - | - | - | 44 | 54 | 75 | 82 | 46 | 65 | 74 | 85 | 26.75 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 2,696 | 3,319 | 3,779 | 4,056 | 4,679 | 4,638 | 5,015 | 6,155 | - |
| Equity And Liabilities | - | - | - | 2,696 | 3,319 | 3,779 | 4,056 | 4,679 | 4,638 | 5,015 | 6,155 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 09 Apr '19 | Mar 2020 07 Apr '20 | Mar 2021 08 Apr '21 | Mar 2022 18 May '22 | Mar 2023 12 Apr '23 | Mar 2024 12 Apr '24 | Mar 2025 09 Apr '25 | Mar 2026 31 Mar '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | 0.44% | 0.74% | 0.76% | 0.45% | - | - | 0.01% | - | - |
| Promoter And Promoter Group | - | - | - | 70.52% | 70.51% | 70.34% | 70.48% | 66.11% | 66.21% | 66.26% | - | - |
| Non Institutions | - | - | - | 9.74% | 9.21% | 8.67% | 8.14% | 7.91% | 7.76% | 7.39% | - | - |
| FII | - | - | - | - | - | - | - | 10.00% | 8.54% | 8.86% | - | - |
| DII | - | - | - | - | - | - | - | 15.98% | 17.49% | 17.48% | - | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | - |
Ajanta Pharma Ltd
Ajanta Pharma Ltd
Ajanta Pharma Ltd is a vertically integrated pharmaceutical company headquartered in Mumbai, India. Established in 1973, the company is engaged in the development, manufacturing, and marketing of quality finished dosages, with a strong focus on branded generics. Ajanta Pharma caters to both regulated and emerging markets, supplying prescription products in therapeutic areas such as cardiology, ophthalmology, dermatology, gastroenterology, and pain management.
The company has a significant presence across Asia, Africa, the Middle East, and select regulated markets including the United States.
With an extensive product portfolio and a robust international footprint, Ajanta Pharma operates multiple state-of-the-art manufacturing and R&D facilities approved by global regulatory agencies such as the US FDA, WHO-GMP, and UK MHRA. The company's operational model emphasizes backward integration and a focused approach toward high-growth specialty segments, enabling it to deliver sustainable business performance and enter new geographies.
Ajanta Pharma earns revenue primarily from the sale of branded generic pharmaceuticals across emerging and regulated markets. The company adopts a differentiated product strategy, focusing on brand-building in selected therapeutic niches such as cardiology, ophthalmology, anti-malarials, and dermatology. Its growth is underpinned by proprietary formulation development, vertical integration, and targeted marketing initiatives to healthcare professionals.
The business is supported by in-house R&D, which accelerates new product launches across global markets, especially the US, Africa, and Asia.
Ajanta Pharma continues to invest in capacity expansion, regulatory accreditation, and deeper market penetration, aiming to strengthen its specialty portfolio. The company's geographic diversification and consistent pipeline of product launches enhance resilience against market-specific volatility. Additionally, Ajanta leverages its US ANDA pipeline and robust supply chain to grow its presence in regulated markets, while maintaining leadership in branded generics within emerging economies.
Featured among Forbes Asia's '200 Best Under a Billion' (2023)
Awarded Silver in 'India CSR Leadership Awards' for sustainability initiatives (2024)
Received India's 'Best Corporate Brand' recognition by Economic Times (2023)
Acknowledged for environmental practices with the CII GreenCo rating (2024)
Ranked among India's Top 50 Most Trusted Pharmaceutical Brands (Brand Trust Report 2024)
Ajanta Pharma Ltd founded in Mumbai, India
Commenced export operations to emerging markets
Listed on the Bombay Stock Exchange (IPO)
Established dedicated R&D center in Mumbai
Received US FDA approval for manufacturing facility at Paithan, Maharashtra
Entered US generics market with first ANDA approval
Commercial launch of key dermatology and ophthalmology products
Inaugurated new formulation plant at Guwahati, Assam
Expanded specialty portfolio with new product launches in the US and Africa
Recognized for sustainability and ESG leadership by industry associations
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon